Theriva BiologicsTOVX +4.52%28 Quick Ratio is 1.63 as of Mar. 2026, which is 41% below its 10-year median of 2.78. GuruFocus rates TOVX with a GF Score™ of 28/100. The stock has 3 warning signs investors should review. Among 1,413 Biotechnology companies, Theriva Biologics ranks worse than 70.7% on this metric.
Theriva Biologics has a quick ratio of 1.63. It generally indicates good short-term financial strength.
The historical rank and industry rank for Theriva Biologics's Quick Ratio or its related term are showing as below:
TOVX'
s Quick Ratio Range Over the Past 10 Years
Min: 0.55 Med: 2.78 Max: 37.06
Current: 1.63
During the past 13 years, Theriva Biologics's highest Quick Ratio was 37.06. The lowest was 0.55. And the median was 2.78.
TOVX's Quick Ratio is ranked worse than 70.7% of 1413
companies
in the Biotechnology industry
Industry Median: 3.6
vs TOVX: 1.63
Theriva Biologics (AMEX:TOVX) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
Theriva Biologics Quick Ratio Related Terms
Theriva Biologics Quick Ratio Historical Data
* Premium members only.
The historical data trend for Theriva Biologics's Quick Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Theriva Biologics's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Theriva Biologics Quick Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Theriva Biologics's Quick Ratio distribution charts can be found below:
* The bar in red indicates where Theriva Biologics's Quick Ratio falls into.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
Theriva Biologics's Quick Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Theriva Biologics (TOVX) has a Quick Ratio of 1.63 as of Mar. 2026. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Theriva Biologics and its competitors. This is 41% below median its historical median of 2.78. Over the past decade, Theriva Biologics' Quick Ratio has ranged from 0.55 to 37.06. According to the industry distribution chart, Theriva Biologics ranks #999 out of 1413 companies in the Biotechnology industry, placing it in the top 70.7%.
Is Theriva Biologics' Quick Ratio too high?
Theriva Biologics' current Quick Ratio of 1.63 is 41% below median its 10-year median of 2.78. Over the past 10 years, this metric has ranged from a low of 0.55 to a high of 37.06. The Biotechnology industry median Quick Ratio is 3.60. Theriva Biologics' value of 1.63 is 54.7% below this industry median. Based on the distribution chart, Theriva Biologics ranks #999 out of 1413 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Theriva Biologics has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Theriva Biologics' Quick Ratio compare to CALC and PHIO?
According to the Biotechnology industry distribution chart, Theriva Biologics ranks #999 out of 1413 companies for Quick Ratio. This places Theriva Biologics in the lower half of its industry. The industry median Quick Ratio is 3.60. Theriva Biologics' value of 1.63 is 54.7% below this benchmark. Historically, Theriva Biologics' own Quick Ratio has ranged from 0.55 to 37.06 over the past decade. While the company's 10-year median is 2.78 vs. the industry median of 3.60, Theriva Biologics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Biotechnology company?
The median Quick Ratio among Biotechnology companies is 3.60, based on 1,413 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Theriva Biologics's current Quick Ratio of 1.63 is 54.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Theriva Biologics and its competitors. For the Biotechnology industry, the median Quick Ratio is 3.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Theriva Biologics's current Quick Ratio is 1.63, which is 41% below median its own 10-year median of 2.78. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Theriva Biologics stock overvalued right now?
Theriva Biologics (TOVX) has a current Quick Ratio of 1.63. The current Quick Ratio is 1.63, which is 41% below median its 10-year median of 2.78 and 54.7% below the Biotechnology industry median of 3.60. Theriva Biologics' overall GF Score™ is 28/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For Theriva Biologics (TOVX), the current Quick Ratio is 1.63 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system. Product Candidates includes SYN-004 (ribaxamase) and SYN-020.
28GF Score
Get the complete analysis for TOVX
Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TOVX has been successfully added to your 
